SEC Form 4 · accession 0001807359-26-000010
Roivant Sciences Ltd. · ROIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Melissa B, Epperly
Director
Period of report
Jun 29, 2026
Accepted (ET)
Jul 1, 2026 · 6:34 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001635088
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jun 29, 2026 | M | 17,750 | $4.46 | A | 34,224 | D | |
| Common SharesF1 | Jun 29, 2026 | S | 15,002 | $34.32 | D | 19,222 | D | |
| Common SharesF2 | Jun 29, 2026 | S | 2,748 | $34.71 | D | 16,474 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $4.46 | Jun 29, 2026 | M | 17,750 | D | — | Jul 19, 2032 | Common Stock | 17,750 | 169,166 | D |
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.65 to $34.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F3Reflects an award of stock options to purchase Common Shares that is fully vested.